Jianlin Gong

List of Publications by Year
in descending order

91 papers	4,844 citations	76326 40 h-index	95266 68 g-index
92 all docs	92 docs citations	92 times ranked	5039 citing authors

#	Article	IF	Citations
1	A Workflow Guide to RNA-seq Analysis of Chaperone Function and Beyond. Methods in Molecular Biology, 2018, 1709, 233-252.	0.9	3
2	A Novel Heat Shock Protein 70-based Vaccine Prepared from DC-Tumor Fusion Cells. Methods in Molecular Biology, 2018, 1709, 359-369.	0.9	4
3	Molecular Chaperone Receptors. Methods in Molecular Biology, 2018, 1709, 331-344.	0.9	8
4	Genotoxic stress induces Scaâ€1â€expressing metastatic mammary cancer cells. Molecular Oncology, 2018, 12, 1249-1263.	4.6	15
5	Extracellular HSPs: The Complicated Roles of Extracellular HSPs in Immunity. Frontiers in Immunology, 2016, 7, 159.	4.8	155
6	Heat Shock Proteins Promote Cancer: It's a Protection Racket. Trends in Biochemical Sciences, 2016, 41, 311-323.	7.5	316
7	Scavenger receptor SREC-I promotes double stranded RNA-mediated TLR3 activation in human monocytes. Immunobiology, 2015, 220, 823-832.	1.9	28
8	HSF1 regulation of Î²-catenin in mammary cancer cells through control of HuR/elavL1 expression. Oncogene, 2015, 34, 2178-2188.	5.9	83
9	Cell Fusion Between Dendritic Cells and Whole Tumor Cells. Methods in Molecular Biology, 2015, 1313, 185-191.	0.9	6
10	Scavenger Receptor SREC-I Mediated Entry of TLR4 into Lipid Microdomains and Triggered Inflammatory Cytokine Release in RAW 264.7 Cells upon LPS Activation. PLoS ONE, 2015, 10, e0122529.	2.5	43
11	LPSâ€activated Scavenger Receptor SRECâ€I can Induce entry of TLR4 into Lipid Microdomains, Mediate Signal Transduction and trigger cytokine release. FASEB Journal, 2015, 29, 888.25.	0.5	1
12	Dendritic-tumor fusion cells in cancer immunotherapy. Discovery Medicine, 2015, 19, 169-74.	0.5	10
13	Chemoimmunotherapy targeting Wilmsâ€™ tumor 1 (WT1)-specific cytotoxic T lymphocyte and helper T cell responses for patients with pancreatic cancer. OncoImmunology, 2014, 3, e958950.	4.6	13
14	Treatment with Chemotherapy and Dendritic Cells Pulsed with Multiple Wilms' Tumor 1 (WT1)â€“Specific MHC Class I/IIâ€“Restricted Epitopes for Pancreatic Cancer. Clinical Cancer Research, 2014, 20, 4228-4239.	7.0	105
15	Hsp90â€“peptide complexes stimulate antigen presentation through the class II pathway after binding scavenger receptor SREC-I. Immunobiology, 2014, 219, 924-931.	1.9	39
16	Hsp70â€“Bag3 Interactions Regulate Cancer-Related Signaling Networks. Cancer Research, 2014, 74, 4731-4740.	0.9	141
17	Induction of antigen-specific cytotoxic T lymphocytes by fusion cells generated from allogeneic plasmacytoid dendritic and tumor cells. International Journal of Oncology, 2014, 45, 470-478.	3.3	7
18	Tumor regression by CD4 T-cells primed with dendritic/tumor fusion cell vaccines. Anticancer Research, 2014, 34, 3917-24.	1.1	14

#	Article	IF	Citations
19	Immunogenic modulation of cholangiocarcinoma cells by chemoimmunotherapy. Anticancer Research, 2014, 34, 6353-61.	1.1	23
20	Cellular and molecular chaperone fusion vaccines: Targeting resistant cancer cell populations. International Journal of Hyperthermia, 2013, 29, 376-379.	2.5	10
21	Targeted imaging of breast tumor progression and therapeutic response in a human uMUCâ€1 expressing transgenic mouse model. International Journal of Cancer, 2013, 132, 1860-1867.	5.1	18
22	Purification, Preparation, and Use of Chaperoneâ€"Peptide Complexes for Tumor Immunotherapy. Methods in Molecular Biology, 2013, 960, 209-217.	0.9	7
23	Fusions between dendritic cells and whole tumor cells as anticancer vaccines. OncoImmunology, 2013, 2, e24437.	4.6	38
24	Immunotherapy of Radioresistant Mammary Tumors with Early Metastasis Using Molecular Chaperone Vaccines Combined with Ionizing Radiation. Journal of Immunology, 2013, 191, 755-763.	0.8	46
25	Improved immunogenicity of fusions between ethanol-treated cancer cells and dendritic cells exposed to dual TLR stimulation. OncoImmunology, 2013, 2, e25375.	4.6	7
26	Strategies to improve the immunogenicity of anticancer vaccines based on dendritic cell/malignant cell fusions. OncoImmunology, 2013, 2, e25994.	4.6	13
27	The combination of TLR2 and TLR4 agonists promotes the immunogenicity of dendritic cell/cancer cell fusions. OncoImmunology, 2013, 2, e24660.	4.6	1
28	Immunotherapy for colorectal cancer. World Journal of Gastroenterology, 2013, 19, 8531.	3.3	76
29	Augmentation of Antitumor Immunity by Fusions of Ethanol-Treated Tumor Cells and Dendritic Cells Stimulated via Dual TLRs through TGF-Î²1 Blockade and IL-12p70 Production. PLoS ONE, 2013, 8, e63498.	2.5	16
30	Combined TLR2/4-Activated Dendritic/Tumor Cell Fusions Induce Augmented Cytotoxic T Lymphocytes. PLoS ONE, 2013, 8, e59280.	2.5	25
31	Characterization of structure and direct antigen presentation by dendritic/tumor-fused cells as cancer vaccines. Anticancer Research, 2013, 33, 347-54.	1.1	16
32	Immunotherapy synergizes with chemotherapy targeting pancreatic cancer. Immunotherapy, 2012, 4, 5-7.	2.0	11
33	Metastasis is an early event in mouse mammary carcinomas and is associated with cells bearing stem cell markers. Breast Cancer Research, 2012, 14, R18.	5.0	56
34	mTOR Is Essential for the Proteotoxic Stress Response, HSF1 Activation and Heat Shock Protein Synthesis. PLoS ONE, 2012, 7, e39679.	2.5	187
35	The Role of Heat Shock Proteins in Antigen Cross Presentation. Frontiers in Immunology, 2012, 3, 63.	4.8	137
36	Heat Shock Proteins: Conditional Mediators of Inflammation in Tumor Immunity. Frontiers in Immunology, 2012, 3, 75.	4.8	40

#	Article	IF	Citations
37	Molecular chaperones in mammary cancer growth and breast tumor therapy. Journal of Cellular Biochemistry, 2012, 113, 1096-1103.	2.6	52
38	Molecular Chaperones and Scavenger Receptors: Binding and Trafficking of Molecular Chaperones by Class F and Class H Scavenger Receptors. Heat Shock Proteins, 2012, , 215-227.	0.2	3
39	Cell Fusion and Dendritic Cell-Based Vaccines. , 2011, , 315-350.		0
40	Preparation of a Heat-Shock Protein 70-Based Vaccine from DCâ€"Tumor Fusion Cells. Methods in Molecular Biology, 2011, 787, 255-265.	0.9	15
41	Investigating Receptors for Extracellular Heat Shock Proteins. Methods in Molecular Biology, 2011, 787, 289-302.	0.9	48
42	Heat shock proteins and cancer vaccines: developments in the past decade and chaperoning in the decade to come. Expert Review of Vaccines, 2011, 10, 1553-1568.	4.4	83
43	Induction of cytotoxic T lymphocytes against ovarian cancerâ€initiating cells. International Journal of Cancer, 2011, 129, 1990-2001.	5.1	41
44	Current Immunotherapeutic Approaches in Pancreatic Cancer. Clinical and Developmental Immunology, 2011, 2011, 1-15.	3.3	66
45	Immunologic Monitoring of Cellular Responses by Dendritic/Tumor Cell Fusion Vaccines. Journal of Biomedicine and Biotechnology, 2011, 2011, 1-13.	3.0	9
46	Dendritic/pancreatic carcinoma fusions for clinical use: Comparative functional analysis of healthy- versus patient-derived fusions. Clinical Immunology, 2010, 135, 384-400.	3.2	19
47	Heat Shock Protein 90 Mediates Efficient Antigen Cross Presentation through the Scavenger Receptor Expressed by Endothelial Cells-I. Journal of Immunology, 2010, 185, 2903-2917.	0.8	95
48	Antigen-Specific Polyclonal Cytotoxic T Lymphocytes Induced by Fusions of Dendritic Cells and Tumor Cells. Journal of Biomedicine and Biotechnology, 2010, 2010, 1-12.	3.0	9
49	Regulation of Tumor Immunity by Tumor/Dendritic Cell Fusions. Clinical and Developmental Immunology, 2010, 2010, 1-14.	3.3	31
50	Radiosensitization of mammary carcinoma cells by telomere homolog oligonucleotide pretreatment. Breast Cancer Research, 2010, 12, R71.	5.0	12
51	A Heat Shock Protein 70-Based Vaccine with Enhanced Immunogenicity for Clinical Use. Journal of Immunology, 2010, 184, 488-496.	0.8	80
52	T Cell Activation by Heat Shock Protein 70 Vaccine Requires TLR Signaling and Scavenger Receptor Expressed by Endothelial Cells-1. Journal of Immunology, 2009, 183, 3092-3098.	0.8	75
53	Cancer Vaccine by Fusions of Dendritic and Cancer Cells. Clinical and Developmental Immunology, 2009, 2009, 1-13.	3.3	28
54	Telomerase deficiency and telomere dysfunction inhibit mammary tumors induced by polyomavirus middle T oncogene. Oncogene, 2009, 28, 4225-4236.	5.9	20

#	Article	IF	Citations
55	Cancer immunotherapy by fusions of dendritic cells and tumor cells. Immunotherapy, 2009, 1, 49-62.	2.0	21
56	Cell fusion: from hybridoma to dendritic cell-based vaccine. Expert Review of Vaccines, 2008, 7, 1055-1068.	4.4	49
57	Heat-shock proteins in cancer vaccines: agents of antigen cross-presentation. Expert Review of Vaccines, 2008, 7, 1019-1030.	4.4	70
58	In vitro generation of cytotoxic and regulatory T cells by fusions of human dendritic cells and hepatocellular carcinoma cells. Journal of Translational Medicine, 2008, 6, 51.	4.4	21
59	Cancer vaccines: methods for inducing immunity. Expert Review of Vaccines, 2008, 7, 861-862.	4.4	1
60	Cell Stress Proteins: Novel Immunotherapeutics. Novartis Foundation Symposium, 2008, 291, 115-136.	1.1	11
61	Synergistic Induction of Antigen-Specific CTL by Fusions of TLR-Stimulated Dendritic Cells and Heat-Stressed Tumor Cells. Journal of Immunology, 2007, 179, 4874-4883.	0.8	34
62	Generation and functional assessment of antigen-specific T cells stimulated by fusions of dendritic cells and allogeneic breast cancer cells. Vaccine, 2007, 25, 2610-2619.	3.8	29
63	Cell surface receptors for molecular chaperones. Methods, 2007, 43, 199-206.	3.8	74
64	Dendritic/tumor fusion cell-based vaccination against cancer. Archivum Immunologiae Et Therapiae Experimentalis, 2007, 55, 281-287.	2.3	25
65	Hsp70-Based Anticancer Vaccines: Chaperoning The Immune Response. , 2007, , 367-382.		2
66	Immunotherapy of Cancer Based on DC-Tumor Fusion Vaccine. Current Immunology Reviews, 2006, 2, 291-304.	1.2	2
67	Enhanced Immunogenicity of Heat Shock Protein 70 Peptide Complexes from Dendritic Cell-Tumor Fusion Cells. Journal of Immunology, 2006, 177, 5946-5955.	0.8	89
68	Induction of heat shock proteins by heregulin Î²1 leads to protection from apoptosis and anchorage-independent growth. Oncogene, 2005, 24, 6564-6573.	5.9	107
69	Assessment of fusion cells from patient-derived ovarian carcinoma cells and dendritic cells as a vaccine for clinical use. Gynecologic Oncology, 2005, 99, 462-471.	1.4	34
70	Message in a bottle: Role of the 70-kDa heat shock protein family in anti-tumor immunity. European Journal of Immunology, 2005, 35, 2518-2527.	2.9	130
71	Induction of antigen-specific CD4- and CD8-mediated T-cell responses by fusions of autologous dendritic cells and metastatic colorectal cancer cells. International Journal of Cancer, 2005, 117, 587-595.	5.1	37
72	Induction of Impaired Antitumor Immunity by Fusion of MHC Class II-Deficient Dendritic Cells with Tumor Cells. Journal of Immunology, 2005, 174, 1274-1280.	0.8	32

#	Article	IF	Citations
73	Dendritic Cells Fused with Allogeneic Colorectal Cancer Cell Line Present Multiple Colorectal Cancerâ€"Specific Antigens and Induce Antitumor Immunity against Autologous Tumor Cells. Clinical Cancer Research, 2005, 11, 7891-7900.	7.0	84
74	How is the immune response affected by hyperthermia and heat shock proteins?. International Journal of Hyperthermia, 2005, 21, 713-716.	2.5	77
75	Expression of a Dominant Negative Heat Shock Factor-1 Construct Inhibits Aneuploidy in Prostate Carcinoma Cells*. Journal of Biological Chemistry, 2004, 279, 32651-32659.	3.4	64
76	Fusion Cell Vaccination of Patients with Metastatic Breast and Renal Cancer Induces Immunological and Clinical Responses. Clinical Cancer Research, 2004, 10, 4699-4708.	7.0	227
77	Development of Antigen-Specific CD8+ CTL in MHC Class I-Deficient Mice through CD4 to CD8 Conversion. Journal of Immunology, 2004, 172, 7848-7858.	0.8	25
78	Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma. British Journal of Haematology, 2004, 125, 343-352.	2.5	74
79	Induction of anti-leukemic cytotoxic T lymphocytes by fusion of patient-derived dendritic cells with autologous myeloblasts. Leukemia Research, 2004, 28, 1303-1312.	0.8	38
80	Dendritic cells fused with human cancer cells: morphology, antigen expression, and T cell stimulation. Clinical Immunology, 2004, 113, 261-269.	3.2	59
81	Immunotherapy of spontaneous mammary carcinoma with fusions of dendritic cells and mucin 1â€positive carcinoma cells. Immunology, 2003, 109, 300-307.	4.4	63
82	Elevated Expression of Heat Shock Factor (HSF) 2A Stimulates HSF1-induced Transcription during Stress. Journal of Biological Chemistry, 2003, 278, 35465-35475.	3.4	91
83	Prevention of Spontaneous Breast Carcinoma by Prophylactic Vaccination with Dendritic/Tumor Fusion Cells. Journal of Immunology, 2003, 170, 1980-1986.	0.8	78
84	The Kinetics of In Vivo Priming of CD4 and CD8 T Cells by Dendritic/Tumor Fusion Cells in MUC1-Transgenic Mice. Journal of Immunology, 2002, 168, 2111-2117.	0.8	66
85	Immunization against murine multiple myeloma with fusions of dendritic and plasmacytoma cells is potentiated by interleukin 12. Blood, 2002, 99, 2512-2517.	1.4	120
86	Vaccination with Allogeneic Dendritic Cells Fused to Carcinoma Cells Induces Antitumor Immunity in MUC1 Transgenic Mice. Clinical Immunology, 2001, 101, 192-200.	3.2	67
87	Preventive antitumor activity against hepatocellular carcinoma (HCC) induced by immunization with fusions of dendritic cells and HCC cells in mice. Journal of Gastroenterology, 2001, 36, 764-771.	5.1	68
88	T cell suppression as a mechanism for tolerance to MUC1 antigen in MUC1 transgenic mice. Breast Cancer Research and Treatment, 2000, 60, 107-115.	2.5	25
89	Fusions of Human Ovarian Carcinoma Cells with Autologous or Allogeneic Dendritic Cells Induce Antitumor Immunity. Journal of Immunology, 2000, 165, 1705-1711.	0.8	211
90	Induction of Antitumor Immunity by Vaccination of Dendritic Cells Transfected with MUC1 RNA. Journal of Immunology, 2000, 165, 5713-5719.	0.8	164

#	Article	IF	Citations
91	Bone Marrow and Peripheral Blood Dendritic Cells From Patients With Multiple Myeloma Are Phenotypically and Functionally Normal Despite the Detection of Kaposiâ€™s Sarcoma Herpesvirus Gene Sequences. Blood, 1999, 93, 1487-1495.	1.4	66